Key result
This review discusses the mechanisms and management of on-target and off-target cardiotoxicities caused by chemotherapeutic agents, including left ventricular dysfunction and hypertension.
Why the study?
What are the mechanisms and management strategies for cardiotoxicity caused by chemotherapeutic agents?
What are the mechanisms and management strategies for cardiotoxicity caused by chemotherapeutic agents?
This review provides a summary of the mechanisms and management of chemotherapy-induced cardiotoxicity, highlighting the need for thorough evaluation in cardio-oncology.
May guide cardio-oncology monitoring; extends mechanistic summaries but leaves optimal strategies open for prospective trials.
Cardiovascular toxicity caused by cancer therapy is a challenging area which needs thorough evaluation and research. Numerous studies, meta-analyses and reviews have been published in the past discussing cardiotoxicity caused by chemotherapeutic agents. A brief review of the on-target and off-target cardiotoxicities caused by chemotherapeutic agents is presented here. Cardiotoxicities are broadly outlined in terms of left ventricular dysfunction, hypertension and thromboembolic events. The mechanisms leading to the cardiotoxicity profiles of various chemotherapeutic agents are discussed. The management of various cardiotoxicities of chemotherapeutic agents is also discussed.
No takes yet. Share an insight, caveat, or question.
Aggarwal et al. (2013) conducted a review in Chemotherapy-related cardiotoxicity. Chemotherapeutic agents was evaluated. This review discusses the mechanisms and management of on-target and off-target cardiotoxicities caused by chemotherapeutic agents, including left ventricular dysfunction and hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: